Cite

HARVARD Citation

    Hsu, J. et al. (n.d.). XL092, a multi-targeted inhibitor of MET, VEGFR2, AXL and MER with an optimized pharmacokinetic profile. European journal of cancer. pp. S16-. [Online]. 
  
Back to record